Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

China · Delayed Price · Currency is CNY

128.71

-9.63 (-6.96%)

Aug 21, 2026, 3:00 PM CST

21.54% (1Y)

Market Cap	34.07B +22.7%
Revenue (ttm)	1.64B +145.6%
Net Income	549.87M
EPS	2.07
Shares Out	264.71M
PE Ratio	62.04
Forward PE	67.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,739,361
Open	134.00
Previous Close	138.34
Day's Range	125.54 - 135.46
52-Week Range	75.10 - 160.00
Beta	-0.11
Analysts	Strong Buy
Price Target	139.05 (+8.03%)
Earnings Date	Aug 1, 2026

About SHA:688266

Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer; and recombinant human thrombin for hemostasis. It also develops gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2009

Employees 1,055

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688266

Full Company Profile

Financial Performance

In 2025, SHA:688266's revenue was 810.48 million, an increase of 52.07% compared to the previous year's 532.95 million. Losses were -162.95 million, 18.2% more than in 2024.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 688266 stock is "Strong Buy." The 12-month stock price target is ¥139.05, which is an increase of 8.03% from the latest price.

Price Target

¥139.05

(8.03% upside)

Analyst Consensus: Strong Buy

Stock Forecasts